Our researchers are currently in need of adult and pediatric study participants to help us pursue better treatments and cures. Participants may receive medical evaluations and procedures, study medication, disease-related education and possible financial compensation for time, travel and participation.
Researchers with the ARGiNAUT clinical trial are investigating a new medication that may help block the formation of scar tissue in the lungs in people with idiopathic pulmonary fibrosis (IPF) and related conditions. Volunteers with IPF are needed. Learn how you can participate.
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
Researchers in the WISPer study are evaluating if an investigational treatment for IPF is safe and helps improve symptoms. Volunteers with IPF are needed.
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
Researchers in the WISPer study are evaluating if an investigational treatment for IPF is safe and helps improve symptoms. Volunteers with IPF are needed.
